nach oben

International Journal of Clinical Pharmacy

Erschienen in:

26.09.2021 | Research Article

Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020

verfasst von: Abdulrahman Alsuhibani, Marwan Alrasheed, Musaab Gari, Ana L. Hincapie, Jeff Jianfei Guo

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background Obesity is a globally growing health problem, and its treatment has been challenging. The use of anti-obesity medications (AOMs) has been associated with severe adverse events (AEs). Several AOMs have been withdrawn from the market owing to documented AEs. Aim To describe, estimate and characterize the frequency of AEs attributable to the use of the AOMs, and investigate previously unreported potential AEs associated with AOMs. Method Using the US FDA Adverse Event Reporting System (FAERS) between January 2013 and June 2020, a retrospective, descriptive analysis was conducted to analyze all major reported AEs and outcomes including death, life-threatening, hospitalization, disability, and required intervention or congenital anomaly. The total numbers of AEs reports, cases, adverse reactions and outcomes were calculated for each medication. Results A total of 18,675 unique AEs reports associated with AOMs used for 15,143 patients. The mean age was 49.8 years [SD 1.83], while most patients were female adults (73.4%). The most frequently reported AEs were nausea and vomiting, followed by dizziness and headache, drug ineffectiveness, cardiovascular diseases, and kidney complications. There were 21,229 unique outcomes, including 1039 deaths (fatality ratio of 4.9% of all analyzed reports), 1613 (7.6%) life-threatening events, 7426 (35%) hospitalizations, and 1249 (5.9%) disability cases. Phentermine/topiramate fatal cases represent 6% of the overall medication's reported AEs. Cardiovascular AEs represented 31%, 23%, and 22% of phentermine, liraglutide, and phentermine/topiramate total AEs, respectively. Conclusion The analysis of FAERS database revealed numerous serious AEs associated with AOMs. These AEs can lead to serious cardiovascular and kidney complications. It is necessary to continue and systematically monitor safety of AOMs’ to optimize patient anti-obesity therapy.

GHO | By category | Overweight / Obesity [Internet]. [cited 2021]. Available from: https://apps.who.int/gho/data/node.main.A896?lang=en.

Products - Data Briefs - Number 360 - February 2020 [Internet]. [cited 2020]. Available from: https://www.cdc.gov/nchs/products/databriefs/db360.htm.

The State of Obesity 2020: Better Policies for a Healthier America - tfah [Internet]. [cited 2020]. Available from: https://www.tfah.org/report-details/state-of-obesity-2020/.

Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161:1581–6.PubMedCrossRef

Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–9.PubMedCrossRef

Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–9.PubMedCrossRef

Cairney J, Wade TJ. Correlates of body weight in the 1994 National Population Health Survey. Int J Obes Relat Metab Disord. 1998;22:584–91.PubMedCrossRef

Williams EP, Mesidor M, Winters K, Dubbert PM, Wyatt SB. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Curr Obes Rep. 2015;4:363–70.PubMedCrossRef

Patterson RE, Frank LL, Kristal AR, White E. A comprehensive examination of health conditions associated with obesity in older adults. Am J Prev Med. 2004;27:385–90.PubMedCrossRef

10.

Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 37.4 million deaths among 30.3 million participants. BMJ. 2016;353:2156.CrossRef

11.

Leblanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:434–47.PubMedCrossRef

12.

Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.PubMedCrossRef

13.

Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.PubMedCrossRef

14.

Neff KJ, Olbers T, le Roux CW. Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes. BMC Med. 2013;11:8.PubMedPubMedCentralCrossRef

15.

Who is a Candidate for Bariatric Surgery? | Patients | ASMBS [Internet]. [cited 2020]. Available from: https://asmbs.org/patients/who-is-a-candidate-for-bariatric-surgery.

16.

Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharmacol. 2009;68:852–60.PubMedPubMedCentralCrossRef

17.

Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity—trends using a population level national database. Obes Surg. 2021;31(3):1105–12.PubMedCrossRef

18.

Rodgers RJ, Tschöp MH, Wilding JPH. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5:621–6.PubMedPubMedCentralCrossRef

19.

Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–8.PubMedCrossRef

20.

James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–17.PubMedCrossRef

21.

Abbott Withdraws Sibutramine From Market [Internet]. [cited 2020]. Available from: https://www.medscape.com/viewarticle/730155.

22.

Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk [Internet]. [cited 2020]. Available from: https://www.medscape.com/viewarticle/925253.

23.

Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf. 2012;11(3):459–71.PubMedCrossRef

24.

Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018;130:173–82.PubMedPubMedCentralCrossRef

25.

Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep. 2018;7:147–61.PubMedCrossRef

26.

Aagaard L, Hansen EH. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics SSRIs and NSAIDs. BMC Clin Pharmacol. 2009;9:4.PubMedPubMedCentralCrossRef

27.

Hatahira H, Abe J, Hane Y, Matsui T, Sasaoka S, Motooka Y, et al. Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. J Pharm Health Care Sci. 2017;3:19.PubMedPubMedCentralCrossRef

28.

Kato Y, Umetsu R, Abe J, Ueda N, Nakayama Y, Kinosada Y, et al. Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. J Pharm Health Care Sci. 2015;1:15.PubMedPubMedCentralCrossRef

29.

Questions and Answers on FDA’s Adverse Event Reporting System (FAERS) | FDA [Internet]. [cited 2021]. Available from: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers.

30.

Drugs@FDA: FDA-Approved Drugs [Internet]. [cited 2020]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/.

31.

Lindquist M, Ståhl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23:533–42.PubMedCrossRef

32.

Aagaard L, Hallgreen CE, Hansen EH. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance. Int J Obes. 2016;40:1742–7.CrossRef

33.

Aagaard L, Strandell J, Melskens L, Petersen PS, Hansen EH. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase^TM. Drug Saf. 2012;35:1171–82.PubMedCrossRef

34.

Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165:1363–9.PubMedCrossRef

35.

Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424–34.PubMedPubMedCentralCrossRef

36.

Kose M, Emet S, Akpinar TS, Ilhan M, Gok AF, Dadashov M, et al. An unexpected result of obesity treatment: orlistat-related acute pancreatitis. Case Rep Gastroenterol. 2015;9:152–5.PubMedPubMedCentralCrossRef

37.

Johansson K, Neovius K, DeSantis SM, Rössner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009;10:564–75.PubMedCrossRef

38.

Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167–72.PubMedCrossRef

39.

Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24:306–13.PubMedCrossRef

40.

Medications Target Long-Term Weight Control | FDA [Internet]. [cited 2021]. Available from: https://www.fda.gov/consumers/consumer-updates/medications-target-long-term-weight-control.

41.

Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14:12–24.PubMedCrossRef

42.

Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33:1299–307.PubMedPubMedCentralCrossRef

43.

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.PubMedCrossRef

44.

Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–42.CrossRef

45.

Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci. 2018;1411:106–19.PubMedCrossRef

46.

Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J Men’s Health. 2021;39(2):208.CrossRef

47.

Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the United States. Am J Med. 2016;129(879):e1-6.

48.

Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311:74–86.PubMedPubMedCentralCrossRef

49.

Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379:1107–17.PubMedCrossRef

50.

Kumar R, Ryan D. Lorcaserin departs, leaving more questions than answers. Obesity (Silver Spring). 2020;28:1167–1167.CrossRef

51.

Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16:1018–22.PubMedPubMedCentralCrossRef

52.

Liraglutide Injection: MedlinePlus Drug Information [Internet]. [cited 2021 ]. Available from: https://medlineplus.gov/druginfo/meds/a611003.html.

53.

U.S. GAO - Obesity Drugs: Few Adults Used Prescription Drugs for Weight Loss and Insurance Coverage Varied [Internet]. [cited 2021]. Available from: https://www.gao.gov/products/GAO-19-577.

Titel: Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020
verfasst von: Abdulrahman Alsuhibani
Marwan Alrasheed
Musaab Gari
Ana L. Hincapie
Jeff Jianfei Guo
Publikationsdatum: 26.09.2021
Verlag: Springer International Publishing
Erschienen in: International Journal of Clinical Pharmacy / Ausgabe 1/2022
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-021-01330-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Factors associated with Turkish pharmacists’ intention to receive COVID-19 vaccine: an observational study

Thank You Reviewers

Evaluation of osimertinib for advanced non-small cell lung cancer with leptomeningeal metastases: a cost-effectiveness and budget impact analysis

Safety and efficacy of transitioning from intravenous to subcutaneous insulin in critically ill patients

Fluoropyridmidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database